コンテンツへスキップ
Merck
  • Association of extreme blood lipid profile phenotypic variation with 11 reverse cholesterol transport genes and 10 non-genetic cardiovascular disease risk factors.

Association of extreme blood lipid profile phenotypic variation with 11 reverse cholesterol transport genes and 10 non-genetic cardiovascular disease risk factors.

Human molecular genetics (2003-09-11)
Alfredo Morabia, Eftihia Cayanis, Michael C Costanza, Barbara M Ross, Maria Sol Flaherty, Gabriela B Alvin, Kamna Das, T Conrad Gilliam
要旨

This study explored the genetic basis of the combination of extreme blood levels of HDL-C and LDL-C, a well-studied endophenotype for CVD, which has several attractive features as a target for genetic analysis: (1) the trait is moderately heritable; (2) non-genetic risk factors account for a significant but still limited portion of the phenotypic variance; (3) it is known to be moderated by a number of gene products. We exhaustively surveyed 11 candidate genes for allelic variation in a random population-based sample characterized for known CVD risk factors and blood lipid profiles. With the goal of generating specific etiological hypotheses, we compared two groups of subjects with extreme lipid phenotypes, from the same source population, using a case-control design. Cases (n=186) were subjects, within the total sample of 1708 people, who scored in the upper tertile of LDL-C and the lowest tertile of HDL-C, while controls (n=185) scored in the lowest tertile of LDL-C and the upper tertile of HDL-C. We used logistic regression and a four-tiered, systematic model building strategy with internal cross-validation and bootstrapping to investigate the relationships between the trait and 275 genetic variants in the presence of 10 non-genetic risk factors. Our results implicate a subset of nine genetic variants, spanning seven candidate genes, together with five environmental risk factors, in the etiology of extreme lipoprotein phenotypes. We propose a model involving these 14 genetic and non-genetic risk factors for evaluation in future independent studies.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
リパーゼ Candida rugosa由来, Type VII, ≥700 unit/mg solid
Sigma-Aldrich
リパーゼ ブタ膵臓由来, Type II, ≥125 units/mg protein (using olive oil (30 min incubation)), 30-90 units/mg protein (using triacetin)
Sigma-Aldrich
リパーゼ・アクリル樹脂 from Candida antarctica, ≥5,000 U/g, recombinant, expressed in Aspergillus niger
Sigma-Aldrich
リパーゼB, Candida antarctica由来, 組換え体 from Aspergillus oryzae, powder, beige, ~9 U/mg
Sigma-Aldrich
リパーゼ ブタ膵臓由来, Type VI-S, ≥20,000 units/mg protein, lyophilized powder
Sigma-Aldrich
リパーゼ from Aspergillus niger, powder (fine), ~200 U/g
Sigma-Aldrich
リパーゼ Candida rugosa由来, lyophilized powder, ≥40,000 units/mg protein
Sigma-Aldrich
リパーゼ Candida sp.(カンジダ属)由来, recombinant, expressed in Aspergillus niger
Sigma-Aldrich
Lipase immobilized from Candida antarctica, beads, slightly brown, >2 U/mg
Sigma-Aldrich
リパーゼ from Rhizomucor miehei, ≥20,000 U/g
Sigma-Aldrich
リパーゼ Pseudomonas cepacia由来, powder, light beige, ≥30 U/mg
Sigma-Aldrich
リパーゼ コムギ胚芽由来, Type I, lyophilized powder, 5-15 units/mg solid
Sigma-Aldrich
リパーゼ from Rhizopus oryzae, powder (fine), ~10 U/mg
Sigma-Aldrich
リパーゼ Candida rugosa由来, powder, yellow-brown, ≥2 U/mg
Sigma-Aldrich
リパーゼ Pseudomonassp. (シュードモナス)由来, Type XIII, lyophilized powder, ≥15 units/mg solid
Sigma-Aldrich
リパーゼ from Aspergillus oryzae, lyophilized, powder, white, ~50 U/mg
Sigma-Aldrich
リパーゼ Candida rugosa由来, lyophilized, powder (fine), 15-25 U/mg
Sigma-Aldrich
リパーゼ from Mucor miehei, lyophilized powder, ≥4,000 units/mg solid (using olive oil)
Sigma-Aldrich
リパーゼ from Rhizopus niveus, powder (fine), ≥1.5 U/mg
Sigma-Aldrich
Lipase A Candida antarctica, recombinant from Aspergillus oryzae, powder, beige, ~2 U/mg
Sigma-Aldrich
リパーゼ from Mucor miehei, powder, slightly brown, ~1 U/mg
Sigma-Aldrich
リパーゼ from Mucor javanicus, lyophilized powder, ≥300 units/mg solid (using olive oil)